Drug-maker filed response in US court yesterday. Under fire in the United States for giving distorted information on the generic drugs it sold, Ranbaxy Laboratories today said that it will file all relevant information within a month after which the legal case initiated against it by the US government will be withdrawn. This is a key disclosure in the response filed by Ranbaxy in a district court in Maryland yesterday against the "motion to compel" filed by the US government on July 3.